"\n\nMolGod<\/database>MOL-GOD<\/source-app>1<\/rec-number>17<\/ref-type>et al.<\/author><\/authors><\/contributors>Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2019<\/year><\/dates><electronic-resource-num>10.1126\/science.aau6323<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC7745125?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>2<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2019<\/year><\/dates><electronic-resource-num>10.1038\/s41467-019-08294-y<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.nature.com\/articles\/s41467-019-08294-y.pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>3<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2015<\/year><\/dates><electronic-resource-num>10.1002\/mds.26269<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/4755510<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>4<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><electronic-resource-num>10.1093\/brain\/awu195<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC4163032?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>5<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><electronic-resource-num>10.1016\/s1474-4422(13)70293-x<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>6<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2013<\/year><\/dates><electronic-resource-num>10.1002\/mds.25364<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>7<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><electronic-resource-num>10.1016\/s0140-6736(14)60683-8<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>8<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Levodopa and the progression of Parkinson's disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2004<\/year><\/dates><electronic-resource-num>10.1056\/nejmoa033447<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa033447?articleTools=true<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>9<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2000<\/year><\/dates><electronic-resource-num>10.1056\/nejm200005183422004<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJM200005183422004?articleTools=true<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>10<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2005<\/year><\/dates><electronic-resource-num>10.1016\/s0140-6736(05)71083-7<\/electronic-resource-num><urls><related-urls><url>http:\/\/hdl.handle.net\/10400.16\/429<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>11<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2004<\/year><\/dates><electronic-resource-num>10.1093\/brain\/awh290<\/electronic-resource-num><urls><related-urls><url>https:\/\/academic.oup.com\/brain\/article-pdf\/127\/12\/2747\/959090\/awh290.pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>12<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1997<\/year><\/dates><electronic-resource-num>10.1073\/pnas.94.7.3363<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/20375<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>13<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2002<\/year><\/dates><electronic-resource-num>10.1136\/jnnp.73.3.267<\/electronic-resource-num><urls><related-urls><url>https:\/\/jnnp.bmj.com\/content\/jnnp\/73\/3\/267.full.pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>14<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2001<\/year><\/dates><electronic-resource-num>10.1002\/mds.1090<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>15<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2003<\/year><\/dates><electronic-resource-num>10.1002\/ana.10609<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>16<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2002<\/year><\/dates><electronic-resource-num>10.1001\/jama.287.13.1653<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>17<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2003<\/year><\/dates><electronic-resource-num>10.1046\/j.1468-1331.2003.00611.x<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>18<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2005<\/year><\/dates><electronic-resource-num>10.1002\/ana.20296<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>19<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2005<\/year><\/dates><electronic-resource-num>10.1002\/mds.20629<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>20<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>The effect of deprenyl and levodopa on the progression of Parkinson's disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1995<\/year><\/dates><electronic-resource-num>10.1002\/ana.410380512<\/electronic-resource-num><\/record>\n<\/records><\/xml>\n"